| 144.15 5.96 (4.31%) | 06-17 13:23 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 172.41 | 1-year : | 185.12 |
| Resists | First : | 147.61 | Second : | 158.5 |
| Pivot price | 141.22 |
|||
| Supports | First : | 130 | Second : | 108.16 |
| MAs | MA(5) : | 140.3 |
MA(20) : | 141.36 |
| MA(100) : | 161.81  |
MA(250) : | 123.04 |
|
| MACD | MACD : | -3 |
Signal : | -3.9 |
| %K %D | K(14,3) : | 56.8 |
D(3) : | 50 |
| RSI | RSI(14): 49.7 |
|||
| 52-week | High : | 200 | Low : | 56.09 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BLTE ] has closed below upper band by 32.2%. Bollinger Bands are 39% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 146.08 - 146.83 | 146.83 - 147.4 |
| Low: | 134.43 - 135.18 | 135.18 - 135.75 |
| Close: | 137 - 138.26 | 138.26 - 139.23 |
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Wed, 17 Jun 2026
Belite Bio Inc (BLTE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Wed, 17 Jun 2026
Belite Bio CMO Scholl sells $1.4m shares from $137.61 to $145.02 - Investing.com
Wed, 17 Jun 2026
Belite Bio (BLTE) CMO-affiliated entity sells 10,000 ADS, retains 32,946 - Stock Titan
Wed, 17 Jun 2026
Belite Bio (BLTE) Stock Could Be 35% Undervalued After Tinlarebant NDA Submission - simplywall.st
Tue, 16 Jun 2026
BLTE (NASDAQ: BLTE) files Rule 144 notice to sell 10,000 ADS under vested RSUs - Stock Titan
Tue, 16 Jun 2026
Belite Bio stock price target maintained at $200 by H.C. Wainwright on NDA completion - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 40 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 44.2 (%) |
| Held by Institutions | 23.6 (%) |
| Shares Short | 1,200 (K) |
| Shares Short P.Month | 1,230 (K) |
| EPS | -2.54 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 20.22 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -13 % |
| Return on Equity (ttm) | -19 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -56.72 |
| PEG Ratio | 0 |
| Price to Book value | 7.12 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|